This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Based in New Haven, CT, Alexion Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of life-transforming drugs, for the treatment of patients with ultra-rare disorders. The company’s complement franchise consists of key growth driver, Soliris, which is approved for the treatment of two severe and ultra-rare disorders resulting from chronic uncontrolled activation of the complement component of the immune system — paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Soliris is also approved for the treatment of generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) antibody-positive. The FDA also approved its long-acting C5 complement inhibitor, Ultomiris, for the treatment of adult patients with PNH, to be administered every eight weeks. In October 2019, the FDA approved the use of Ultomiris as a treatment for adult and pediatric (one month of age or older) patients with aHUS to inhibit complement-mediated TMA.
5 Top Value Picks to Counter Recent Stock Market Softness
by Nalak Das
The stable economic fundamentals of the United States have raised the possibility of the recent stock market volatility being a transitory phase and markets continuing their long-term uptrend.
Apellis' (APLS) PNH Drug Betters Alexion's Soliris in Study
by Zacks Equity Research
Apellis Pharmaceuticals' (APLS) experimental drug pegcetacoplan outperformed Alexion's blockbuster medicine, Soliris, in a phase III head-to-head study. Shares soar.
3 Pharma & Biotech Pipeline Areas to Keep an Eye on in 2020
by Kinjel Shah
Here we present three non-cancer therapeutic areas wherein pipeline developments are expected to garner a lot of interest in 2020.
Alexion Pharmaceuticals (ALXN) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Alexion Pharmaceuticals (ALXN) closed the most recent trading day at $106.58, moving +0.16% from the previous trading session.
Why Alexion (ALXN) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Alexion (ALXN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Walgreens Boots (WBA) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Higher comparable pharmacy sales and expanded comparable prescription volume are likely to have aided growth in Walgreens Boots' (WBA) Retail Pharmacy USA during the first quarter of fiscal 2020.
Alexion (ALXN) is an Incredible Growth Stock: 3 Reasons Why
by Zacks Equity Research
Alexion (ALXN) could produce exceptional returns because of its solid growth attributes.
Incyte's (INCY) Itacitinib Fails in Late-Stage GVHD Study
by Zacks Equity Research
Incyte (INCY) fails to meet goals in the phase III study on itacitinib for the treatment of first-line acute GVHD.
Amicus Progresses on Pipeline Development Amid Competition
by Zacks Equity Research
Amicus (FOLD) progresses with the development of its pipeline. However, the company faces substantial competition.
Global Blood (GBT) Shares Double in a Year, Focus on Oxbryta
by Zacks Equity Research
Shares of Global Blood Therapeutics (GBT) have gained in the past year as its lead candidate voxelotor gets FDA approval for the treatment of SCD in patients aged 12 years or above.
4 Reasons Why Investors Should Buy Alexion (ALXN) in 2020
by Zacks Equity Research
Alexion's (ALXN) growth prospects look strong for 2020 as Soliris maintains momentum and Ultomiris gains further traction.
Keysight, Analog Devices, Alexion, Amarin and Cellectis highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Keysight, Analog Devices, Alexion, Amarin and Cellectis highlighted as Zacks Bull and Bear of the Day
New Strong Buy Stocks for January 2nd
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for today:
All You Need to Know About Alexion (ALXN) Rating Upgrade to Strong Buy
by Zacks Equity Research
Alexion (ALXN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Alexion Pharmaceuticals (ALXN) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Alexion Pharmaceuticals (ALXN) closed at $108.15, marking a +0.75% move from the previous day.
3 Biotech Stocks Likely to Maintain Solid Momentum in 2020
by Ekta Bagri
With the biotech sector gaining steam in recent times, we shortlist three biotech stocks that are set to maintain momentum in 2020.
Gilead (GILD) Partners With Eisai for RA Candidate in Japan
by Zacks Equity Research
Gilead Sciences (GILD) collaborates with Eisai for the distribution and co-promotion of its rheumatoid arthritis candidate, filgotinib. The companies will jointly commercialize the drug, if approved.
Incyte (INCY) Surges 44% YTD on Jakafi's Strong Performance
by Zacks Equity Research
Incyte (INCY) outperforms the industry year to date on strong Jakafi sales.
Create a Value-Based Portfolio With These 4 Low P/CF Stocks
by Sumit Singh
Investing in stocks based on value analysis is generally considered one of the best practices. In value investing, investors pick stocks that are usually cheap but fundamentally sound.
Alexion Pharmaceuticals (ALXN) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Alexion Pharmaceuticals (ALXN) closed at $110.46 in the latest trading session, marking a +0.65% move from the prior day.
Has Alexion Pharmaceuticals (ALXN) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (ALXN) Outperforming Other Medical Stocks This Year?
5 Low Price-to-Book Value Stocks to Buy as 2020 Nears
by Kinjel Shah
P/B ratio is emerging as a convenient tool for identifying low-priced stocks with high-growth prospects.
ALXN vs. HZNP: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ALXN vs. HZNP: Which Stock Is the Better Value Option?
Biotech Stock Outlook: M&A Activity Retains Growth Streak
by Ekta Bagri
The biotech sector enjoys a good run in 2019 on the back of the M&A activities and positive pipeline updates underway. We expect this momentum to stay in 2020 as well.
Biotech Stock Roundup: AMRN Stock Up, Pipeline Updates from GILD, BIIB, AMGN & More
by Zacks Equity Research
The biotech sector was in focus this week with pipeline and regulatory updates from quite a few players.